Publications

Detailed Information

Moxifloxacin-Containing Triple Therapy as Second-Line Treatment for Helicobacter pylori Infection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rate

DC Field Value Language
dc.contributor.authorYoon, Hyuk-
dc.contributor.authorKim, Nayoung-
dc.contributor.authorLee, Byoung Hwan-
dc.contributor.authorHwang, Tae Jun-
dc.contributor.authorPark, Young Soo-
dc.contributor.authorJung, Hyun Chae-
dc.contributor.authorSong, In Sung-
dc.contributor.authorNam, Ryoung Hee-
dc.contributor.authorLee, Dong Ho-
dc.date.accessioned2012-05-24T06:32:33Z-
dc.date.available2012-05-24T06:32:33Z-
dc.date.issued2009-10-
dc.identifier.citationHELICOBACTER; Vol.14 5; 77-85ko_KR
dc.identifier.issn1083-4389-
dc.identifier.urihttps://hdl.handle.net/10371/76426-
dc.description.abstractBackground and Aim: The aim of this study was to evaluate the efficacy of a moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection. We also investigated the effect of treatment duration and antibiotic resistance on the eradication rate of this therapy. Methods: We prospectively enrolled patients found to have persistent H. pylori infections after failure of first-line proton-pump inhibitor-based triple therapy. Patients took moxifloxacin (400 mg q.d.), amoxicillin (1000 mg b.i.d.), and esomeprazole (20 mg b.i.d.). The eradication rate, drug compliance, and adverse event rates were evaluated. Minimal inhibitory tests were performed for moxifloxacin and amoxicillin by the agar dilution method. Results: In 2004, 41 patients were treated for 7 days. The intention-to-treat and per-protocol eradication rates (ITT/PP) were 75.6/83.8%. Moxifloxacin resistance was 5.6%. Therapy was extended to 10 days during 2005-2006 and 139 patients were treated. The ITT/PP eradication rates were 71.9/82.6%; moxifloxacin resistance had increased to 12%. The final group of 181 patients in 2007-2008 who were treated for 14 days also had low eradication rates (68/79.9%), but there was no statistical significance in the efficacy among the treatment periods. Moxifloxacin resistance in 2007-2008 was 28.2%. Side-effect increased with treatment duration (i.e., 9.8, 12.2, and 25.4% at 7, 10, and 14 days, respectively, p = .001). Conclusion: The 7-day moxifloxacin-containing triple therapy produced an unacceptably low eradication rate. Increasing the duration of therapy was expected to increase the eradication rate, but the expected increased did not materialize, most likely because of coincident marked increase in the prevalence of resistance to moxifloxacin. Tailored treatment based on antibiotic susceptibility testing might be more effective in the achievement of high eradication rate when rapid antibiotic resistance such as moxifloxacin is occurring.ko_KR
dc.language.isoenko_KR
dc.publisherWILEY-BLACKWELL PUBLISHING, INCko_KR
dc.subjectH. pyloriko_KR
dc.subjecteradicationko_KR
dc.subjectresistanceko_KR
dc.subjectsecond-lineko_KR
dc.subjectmoxifloxacinko_KR
dc.titleMoxifloxacin-Containing Triple Therapy as Second-Line Treatment for Helicobacter pylori Infection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rateko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor윤혁-
dc.contributor.AlternativeAuthor김나영-
dc.contributor.AlternativeAuthor이병환-
dc.contributor.AlternativeAuthor황태준-
dc.contributor.AlternativeAuthor이동호-
dc.contributor.AlternativeAuthor박영수-
dc.contributor.AlternativeAuthor남령희-
dc.contributor.AlternativeAuthor정현채-
dc.contributor.AlternativeAuthor송인성-
dc.citation.journaltitleHELICOBACTER-
dc.description.citedreferenceDi Caro S, 2009, DIGEST LIVER DIS, V41, P480, DOI 10.1016/j.dld.2008.09.013-
dc.description.citedreferenceHung KH, 2009, HELICOBACTER, V14, P61, DOI 10.1111/j.1523-5378.2009.00655.x-
dc.description.citedreferenceKanizaj TF, 2009, HELICOBACTER, V14, P29, DOI 10.1111/j.1523-5378.2009.00656.x-
dc.description.citedreferenceBago J, 2009, WIEN KLIN WOCHENSCHR, V121, P47, DOI 10.1007/s00508-008-1122-2-
dc.description.citedreferenceKilic ZMY, 2008, DIGEST DIS SCI, V53, P3133, DOI 10.1007/s10620-008-0285-z-
dc.description.citedreferenceKawai T, 2008, J GASTROEN HEPATOL, V23, pS171, DOI 10.1111/j.1440-1746.2008.05408.x-
dc.description.citedreferenceGisbert JP, 2008, WORLD J GASTROENTERO, V14, P5385, DOI 10.3748/wjg.14.5385-
dc.description.citedreferenceKang JM, 2007, HELICOBACTER, V12, P623-
dc.description.citedreferenceUygun A, 2007, J DIG DIS, V8, P211, DOI 10.1111/j.1443-9573.2007.00308.x-
dc.description.citedreferenceSezgin O, 2007, HELICOBACTER, V12, P518-
dc.description.citedreferenceChey WD, 2007, AM J GASTROENTEROL, V102, P1808, DOI 10.1111/j.1572-0241.2007.01393.x-
dc.description.citedreferenceFischbach L, 2007, ALIMENT PHARM THERAP, V26, P343, DOI 10.1111/j.1365-2036.2007.03386.x-
dc.description.citedreferenceMalfertheiner P, 2007, GUT, V56, P772, DOI 10.1136/gut.2006.101634-
dc.description.citedreferenceBago P, 2007, WIEN KLIN WOCHENSCHR, V119, P372, DOI 10.1007/s00508-007-0807-2-
dc.description.citedreferenceZagari RM, 2007, GUT, V56, P475, DOI 10.1136/gut.2006.102269-
dc.description.citedreferenceCarothers JJ, 2007, CLIN INFECT DIS, V44, pE5-
dc.description.citedreferencePaoluzi P, 2006, HELICOBACTER, V11, P562-
dc.description.citedreferenceKadaylfci A, 2006, CLIN THER, V28, P1960, DOI 10.1016/j.clinthera.2006.11.011-
dc.description.citedreferenceKim N, 2006, J CLIN GASTROENTEROL, V40, P683-
dc.description.citedreferenceSaad RJ, 2006, AM J GASTROENTEROL, V101, P488, DOI 10.1111/j.1572-0241.2006.00455.x-
dc.description.citedreferenceCheon JH, 2006, HELICOBACTER, V11, P46-
dc.description.citedreferenceWong WM, 2006, ALIMENT PHARM THERAP, V23, P421, DOI 10.1111/j.1365-2036.2006.02764.x-
dc.description.citedreferenceLEE JH, 2006, KOREAN J GASTROENTER, V48, P19-
dc.description.citedreferenceGisbert JP, 2006, ALIMENT PHARM THERAP, V23, P35, DOI 10.1111/j.1365-2036.2006.02737.x-
dc.description.citedreferenceTHONGNGAM D, 2006, J MED ASS THAI S3, V89, pS119-
dc.description.citedreferenceKANG MS, 2006, KOREAN J GASTROENTER, V47, P30-
dc.description.citedreferenceKim JM, 2005, J ANTIMICROB CHEMOTH, V56, P965, DOI 10.1093/jac/dki334-
dc.description.citedreferenceMatsumoto Y, 2005, DIGEST LIVER DIS, V37, P821, DOI 10.1016/j.dld.2005.06.002-
dc.description.citedreferenceNista EC, 2005, ALIMENT PHARM THERAP, V21, P1241, DOI 10.1111/j.1365-2036.2005.02412.x-
dc.description.citedreferenceKim JM, 2004, ANTIMICROB AGENTS CH, V48, P4843, DOI 10.1128/AAC.48.12.4843-4847.2004-
dc.description.citedreferenceSchabereiter-Gurtner C, 2004, J CLIN MICROBIOL, V42, P4512, DOI 10.1128/JCM.42.10.4512-4518.2004-
dc.description.citedreferenceBall P, 2004, CLIN THER, V26, P940-
dc.description.citedreferenceLamouliatte H, 2003, ALIMENT PHARM THERAP, V18, P791, DOI 10.1046/j.1365-2036.2003.01759.x-
dc.description.citedreferenceFORD A, 2003, CAN J GASTROENTEROL, V17, pB36-
dc.description.citedreferenceSuerbaum S, 2002, NEW ENGL J MED, V347, P1175-
dc.description.citedreferenceGisbert JP, 2002, ALIMENT PHARM THERAP, V16, P1047-
dc.description.citedreferenceMichopoulos S, 2000, ALIMENT PHARM THERAP, V14, P737-
dc.description.citedreferenceGraham DY, 2000, ALIMENT PHARM THERAP, V14, P745-
dc.description.citedreferenceCalvet X, 2000, ALIMENT PHARM THERAP, V14, P603-
dc.description.citedreferenceRealdi G, 1999, HELICOBACTER, V4, P106-
dc.description.citedreferenceVersalovic J, 1996, ANTIMICROB AGENTS CH, V40, P477-
dc.description.citedreferenceMOORE RA, 1995, ANTIMICROB AGENTS CH, V39, P107-
dc.description.tc11-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share